Abrocitinib therapy effective in patients with Atopic dermatitis: Study

A new study published in the International Journal of Dermatology suggests that abrocitinib is an effective therapy for atopic dermatitis (AD) since it is well-tolerated with few major adverse events. Atopic dermatitis is projected to affect more than 20% of children and 1% to 3% of adults. Thereby, reducing symptoms, avoiding exacerbations and lowering treatment risks are the major objectives of therapy. The topical treatment with topical corticosteroids (TCS) or calcineurin inhibitors is the standard of care. One particular inhibitor of Janus kinase (JAK)1 is called bracitinib and the itching and eczema is decreased when this mediator is inhibited. this study by Jose Carlos Armario-Hita and team assessed the safety and short-term efficacy of abrocitinib in individuals with moderate-to-severe AD in a real-world context.

This retrospective multicenter study included adult patients with moderate-to-severe AD who began abrocitinib medication during May 1, 2023 and September 30, 2023, in Fifteen Spanish hospitals. The treatment dosages were either 100 or 200 mg per day which was based on a clinical evaluation. Data on patient demographics, history of AD, comorbidities, past therapies and markers of disease severity, such as Peak Pruritus NRS, body surface area, ratings at baseline, 4, 12, and 24 weeks, Eczema Area and Severity Index (EASI) and SCORing atopic dermatitis (SCORAD) were meticulously gathered. The Dermatology Life Quality Index (DLQI) was utilized to quantify quality of life, while several biochemical indicators and the monitoring of adverse events were used to evaluate safety.